Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.

ABSTRACT:

Background

The clinical features, liver histology, and genetic variants in 57 patients with moderate to severe immune-mediated liver injury from checkpoint inhibitors (ILICI) are presented.

Methods

Between 2010 and 2022, 57 high-causality ILICI cases were enrolled in the Drug-Induced Liver Injury Network. HLA and selected candidate gene variants were tested for association with ILICI risk compared to the general population and other DILI controls.

Results

The 57 high-causality cases were attributed to pembrolizumab (16), ipilimumab (15), ipilimumab and nivolumab (13), and other immune checkpoint inhibitors (13) and occurred at a median of 72 days after the first infusion. Median age was 57.8 years, 66% male, and 89% were non-Hispanic Whites. At DILI onset, 53% had hep

SUBMITTER: Fontana RJ 

PROVIDER: S-EPMC11357698 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature